Baseline Characteristics of the Patients
| . | Training . | Control . | Significance of P . |
|---|---|---|---|
| No. | 33 | 37 | |
| Age (yr) | 39 ± 10 | 40 ± 11 | .52 |
| Gender | |||
| 23 female, | 28 female, | .75 | |
| 10 male | 9 male | ||
| Body-mass-index | 25 ± 6 | 24 ± 4 | .30 |
| Diagnosis: | |||
| Breast cancer | 16 | 19 | |
| Metastatic breast cancer | 7 | 4 | |
| Germ cell cancer | 6 | 7 | |
| Sarcoma | 2 | 3 | |
| Small cell lung carcinoma | — | 1 | |
| Non-small cell lung carcinoma | 1 | 2 | |
| Adenocarcinoma | 1 | — | |
| Neuroblastoma | — | 1 | |
| Chemotherapy: | |||
| VIC | 27 (81%) | 30 (81%) | |
| VIC-E | 6 (9%) | 7 (9%) | |
| Mean no. of chemotherapy cycles preceding HDC | 1.8 ± 0.4 | 1.8 ± 0.5 | .65 |
| Dose of carboplatin (mg) | 429 ± 103 | 395 ± 100 | .17 |
| Retransfunded stem cells (106/kg body weight) | 4.65 ± 3.5 | 3.90 ± 2.9 | .34 |
| . | Training . | Control . | Significance of P . |
|---|---|---|---|
| No. | 33 | 37 | |
| Age (yr) | 39 ± 10 | 40 ± 11 | .52 |
| Gender | |||
| 23 female, | 28 female, | .75 | |
| 10 male | 9 male | ||
| Body-mass-index | 25 ± 6 | 24 ± 4 | .30 |
| Diagnosis: | |||
| Breast cancer | 16 | 19 | |
| Metastatic breast cancer | 7 | 4 | |
| Germ cell cancer | 6 | 7 | |
| Sarcoma | 2 | 3 | |
| Small cell lung carcinoma | — | 1 | |
| Non-small cell lung carcinoma | 1 | 2 | |
| Adenocarcinoma | 1 | — | |
| Neuroblastoma | — | 1 | |
| Chemotherapy: | |||
| VIC | 27 (81%) | 30 (81%) | |
| VIC-E | 6 (9%) | 7 (9%) | |
| Mean no. of chemotherapy cycles preceding HDC | 1.8 ± 0.4 | 1.8 ± 0.5 | .65 |
| Dose of carboplatin (mg) | 429 ± 103 | 395 ± 100 | .17 |
| Retransfunded stem cells (106/kg body weight) | 4.65 ± 3.5 | 3.90 ± 2.9 | .34 |
Values are expressed as mean ± SD.